Posted 22 October, 2021
Xilio Therapeutics, Inc. IPO completed
IPO completed detected for ticker Nasdaq:XLO in a 424B4 filed on 22 October, 2021.
This is our initial public offering, and no public market currently exists for our common stock.
Don't know how to trade IPO completion? Read Initial Public Offerings.
Overview of Xilio Therapeutics, Inc.
Health Care/Life Sciences • Biotechnology
Xilio Therapeutics, Inc. operates as a biotechnology company. It focuses on harnessing the immune system to achieve deep and durable clinical responses in cancer. The company uses its proprietary geographically precise solutions platform to rapidly engineer novel molecules, including cytokines and other biologics. Xilio Therapeutics was founded by John C. Williams and Ulrich Rodeck in June 2015 and is headquartered in Waltham, MA.Market Cap
$20.1M
View Company Details
$20.1M
Interested in special situations?
Join Tickerverse
- customize event filters
- create watchlists, bookmarks
- get email notifications for the latest special situations
- browse and analyze public companies, executives and SEC filings
Tickerverse is a great way to find investment opportunities in corporate actions.
By signing up you agree to our Terms of Service and Privacy Policy.